

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/194,356DATE: 01/06/2000
TIME: 01:13:02

INPUT SET: S34376.raw

This Raw Listing contains the General
Information Section and those Sequences
containing ERRORS.

SEQUENCE LISTING

(1) General Information:

- (i) APPLICANTS: Dario NERI,
Barbara CARNEMOLLA,
Annalisa SIRI,
Enrica BALZA,
Patrizia CASTELLANI,
Alessandro PINI,
Luciano ZARDI,
Greg Paul WINTER,
Giovanni NERI,
Laura BORSI
- (ii) TITLE OF INVENTION: ANTIBODIES TO THE ED-B
DOMAIN OF FIBRONECTIN, THEIR CONSTRUCTION AND
USES
- (iii) NUMBER OF SEQUENCES: 12
- (iv) CORRESPONDENCE ADDRESS:
- (A) ADDRESSEE: HEDMAN, GIBSON & COSTIGAN, P.C.
(B) STREET: 1185 Avenue of the Americas
(C) CITY: New York
(D) STATE: New York
(E) COUNTRY: USA
(F) ZIP: 10036-2646
- (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb
storage
(B) COMPUTER: IBM PS/2
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: Word Perfect 5.1
- (vi) ^{CURRENT} CURRENT APPLICATION DATA:
- (A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:

Does Not Comply
Corrected Diskette Needed

FYI:
all U.S.
applications
filed on or
after July 1, 1998,
and which
do not claim
a prior U.S.
application,
need to be in
new Sequence
Rules format.
See sample
new format
Sequence Listing,
attached in back

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/194,356DATE: 01/06/2000
TIME: 01:13:02

INPUT SET: S34376.raw

46
47 (A) APPLICATION NUMBER: 9610967.3
48 (B) FILING DATE: May 24, 1996
49
50 (viii) ATTORNEY/AGENT INFORMATION:
51
52 (A) NAME: Costigan, James V.
53 (B) REGISTRATION NUMBER: 25,669
54 (C) REFERENCE/DOCKET NUMBER: 515-4132
55
56 (ix) TELECOMMUNICATION INFORMATION:
57
58 (A) TELEPHONE: (212) 302-8989
59 (B) TELEFAX: (212) 302-8998
60

ERRORED SEQUENCES FOLLOW:

108 (2) INFORMATION FOR SEQ ID NO:4:
109
110 (i) SEQUENCE CHARACTERISTICS:
111
--> 112 (A) LENGTH: 69 base pairs
113 (B) TYPE: nucleic acid
114 (C) STRANDEDNESS: single
115 (D) TOPOLOGY: linear
116
117 (ii) MOLECULE TYPE: cDNA
118
119 (iii) SEQUENCE DESCRIPTION: SEQ ID NO:4:
120
121 CTTGGTCCCT CCGCCGAATA CCACMNNMNN MNNMNNMNNM
--> 122 NNAGAGGAGT TACAGTAATA GTCAGCCTC 69
123

*per 1.822 of sequence
Rules, insert the
cumulative base total
at the right margin'
40 of each
line*

124 (2) INFORMATION FOR SEQ ID NO:5:
125
126 (i) SEQUENCE CHARACTERISTICS:
127
--> 128 (A) LENGTH: 54 base pairs
129 (B) TYPE: nucleic acid
130 (C) STRANDEDNESS: single
131 (D) TOPOLOGY: linear
132
133 (ii) MOLECULE TYPE: cDNA
134
135 (iii) SEQUENCE DESCRIPTION: SEQ ID NO:5:
136
137 ATTGCTTTTC CTTTTTGCGG CCGCGCCTAG GACGGTCAGC
--> 138 TTGGTCCCTC CGCC 54

40 ← insert

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/194,356DATE: 01/06/2000
TIME: 01:13:02

INPUT SET: S34376.raw

139

178 (2) INFORMATION FOR SEQ ID NO:8:

179

180 (i) SEQUENCE CHARACTERISTICS:

181

182 (A) LENGTH: 8 amino acids

183 (B) TYPE: amino acid

184 (C) STRANDEDNESS: single

185 (D) TOPOLOGY: linear

186

187 (ii) MOLECULE TYPE: peptide

188

--> 189 (iii) SEQUENCE DESCRIPTION: SEQ ID NO:7:

190

191 Pro Phe Glu His Asn Leu Val Val

192 1 5

193

305 (2) INFORMATION FOR SEQ ID NO:12:

306

307 (i) SEQUENCE CHARACTERISTICS:

308

--> OK 309 (A) LENGTH: 109 amino acids

310 (B) TYPE: amino acid

311 (C) STRANDEDNESS: single

312 (D) TOPOLOGY: linear

313

314 (ii) MOLECULE TYPE: protein

315

316 (iii) ORIGINAL SOURCE:

317

318 (A) STRAIN: CGS2

319

320 (iii) SEQUENCE DESCRIPTION: SEQ ID NO:12:

321

322 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala

323 1 5 10

--> 324 Leu Gly Gln Thr Val Arg Ile Thr Cys Gln Gly Asp Ser

325 15 20 25

326 Leu Arg Ser Tyr Tyr Ala Ser Trp Tyr Gln Gln Lys Pro

327 30 35

328 Gly Gln Ala Pro Val Leu Val Ile Tyr Gly Lys Asn Asn

329 40 45 50

--> 330 Arg Pro Ser Cly Ile Pro Asp Arg Phe Ser Gly Ser Ser

331 55 60 65

332 Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln

333 70 75

334 Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Ser Pro

335 80 85 90

336 Phe Glu His Asn Leu Val Val Phe Gly Gly Gly Thr Lys

337 95 100

338 Leu Thr Val Leu Gly

involved
amino
acid
designation
→

PAGE: 4

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/194,356

DATE: 01/06/2000
TIME: 01:13:02

INPUT SET: S34376.raw

339
340

105

SEQUENCE VERIFICATION REPORT
PATENT APPLICATION US/09/194,356DATE: 01/06/2000
TIME: 01:13:03**INPUT SET: S34376.raw**

Line	Error	Original Text
112	Entered (69) and Calc. Seq. Length (29) differ	(A) LENGTH: 69 base pairs
122	# of Sequences for line conflicts w/ running total	NNAGAGGAGT TACAGTAATA GTCAGCCTC 69
128	Entered (54) and Calc. Seq. Length (14) differ	(A) LENGTH: 54 base pairs
138	# of Sequences for line conflicts w/ running total	TTGGTCCCTC CGCC 54
189	Wrong Sequence Number	(iii) SEQUENCE DESCRIPTION: SEQ ID NO:7:
309	Entered (109) and Calc. Seq. Length (107) differ	(A) LENGTH: 109 amino acids
324	Wrong Amino Acid Designator	Leu Gly Gin Thr Val Arg Ile Thr Cys Gln Gly Asp Ser
330	Wrong Amino Acid Designator	Arg Pro Ser Cly Ile Pro Asp Arg Phe Ser Gly Ser Ser

Appendix A To Subpart G to Part I—Sample Sequence Listing

<110> Smith, John

Smith, Jane

<120> Example of a Sequence Listing

<130> 01-00001

<140> US 08/999,999

<141> 1998-02-28

<150> EP 91000000

<151> 1997-12-31

Please consult

<160> 2

<170> PatentIn ver. 2.0

<210> 1

<211> 403

<212> DNA

<213> Paramecium aurelia

<220>

<221> CDS

<222> 341..394

<300>

<301> Doe, Richard

<302> Isolation and Characterization of a Gene Encoding a

Protease from Paramecium sp.

<303> Journal of Fictional Genes

<304> 1

<305> 4

<306> 1 - 7

<307> 1988-06-20

<400> 1

ctactctact ctactctcat ctactatctt ctttggatct ctgagtctgc ctgagtggta 60

ctcttgagtc ctggagatct ctctctcac atgtgatcgt cgagactgac cgatagatcg 120

ctgactgact ctgagatagt cgagcccgtta cgagaccgtt cgaggggtgac agagagtggg 180

cgcggtgcgcg cagagcgccg cgccgggtgcg cgcgcgagtg cgcggtgggc cgcgcgaggg 240

ctttcgcggc agcgggcggc ctttcgggcg cgcgcccgtc cgccctaga cctgagaggt 300

cttctcttcc ctctcttca ctgagaggt ctatatatac atg gtt tca atg ttc 355

Met Val Ser Met Phe

agc ttg tct ttc aaa tgg cct gga ttt tgt ttg ttt gtt tgtttgctc 403

Ser Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu Phe Val

- 10

15

<210> 2

<211> 18

<212> PRT

<213> Paramecium aurelia

<400> 2

Met Val Ser Met Phe Ser Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu

1

5

10

15

Phe Val

ed: May 22, 1998.

A. Lehman,

ant Secretary of Commerce and
issioner of Patents and Trademarks.

oc. 98-14194 Filed 5-29-98; 8:45 am]

1 CODE 3510-16-C

identifiers and their accompanying information as shown in the following table. The numeric identifier shall be used only in the "Sequence Listing." The order and presentation of the items of information in the "Sequence Listing" shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the "Sequence Listing." The following table illustrates the numeric identifiers.

Numeric Identifier	Definition	Comments and Format	Mandatory (M) or Optional (O)
<110>	Applicant	Preferably max. of 10 names; one name per line; preferable format: Surname, Other Names and/or Initials	M
<120>	Title of Invention		M
<130>	File Reference	Personal file reference	M when filed prior to assignment of appl. number
<140>	Current Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if available
<141>	Current Filing Date	Specify as: yyyy-mm-dd	M, if available
<150>	Prior Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if applicable include priority documents under 35 USC 119 and 120
<151>	Prior Application Filing Date	Specify as: yyyy-mm-dd	M, if applicable
<160>	Number of SEQ ID NOs	Count includes total number of SEQ ID NOs	M
<170>	Software	Name of software used to create the Sequence Listing	O
<210>	SEQ ID NO:#:	Response shall be an integer representing the SEQ ID NO shown	M
<211>	Length	Respond with an integer expressing the number of bases or amino acid residues	M

<212>	Type	Whether presented sequence molecule is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/RNA molecule shall be further described in the <220> to <223> feature section.	M
<213>	Organism	Scientific name, i.e. Genus/species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section.	M
<220>	Feature	Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence.	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<221>	Name/Key	Provide appropriate identifier for feature, preferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence
<222>	Location	Specify location within sequence; where appropriate state number of first and last bases/amino acids	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified

		in feature	base was used in a sequence
<223>	Other Information	Other relevant information; four lines maximum	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<300>	Publication Information	Leave blank after <300>	O
<301>	Authors	Preferably max of ten named authors of publication; specify one name per line; preferable format: Surname, Other Names and/or Initials	O
<302>	Title		O
<303>	Journal		O
<304>	Volume		O
<305>	Issue		O
<306>	Pages		O
<307>	Date	Journal date on which data published; specify as yyyy-mm-dd, MMM-yyyy or Season-yyyy	O
<308>	Database Accession Number	Accession number assigned by database including database name	O
<309>	Database Entry Date	Date of entry in database; specify as yyyy-mm-dd or MMM-yyyy	O
<310>	Patent Document Number	Document number; for patent-type citations only. Specify as, for example, US 07/999,999	O

<311>	Patent Filing Date	Document filing date, for patent-type citations only; specify as yyyy-mm-dd	O
<312>	Publication Date	Document publication date, for patent-type citations only; specify as yyyy-mm-dd	O
<313>	Relevant Residues	FROM (position) TO (position)	O
<400>	Sequence	SEQ ID NO should follow the numeric identifier and should appear on the line preceding the actual sequence	M

5. Section 1.824 is revised to read as follows:

1.824 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.

(a) The computer readable form required by 1.821(e) shall meet the following specifications:

(1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media outlined in paragraph (c) of this section.

(2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.

(3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.

(4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.

(5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" file.

(6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.

(b) Computer readable form submissions must meet these format requirements:

(1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;

(2) Operating System: MS-DOS, Unix or Macintosh;